Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -50.49% is 86% below its 5-year average of -27.11%, near the low end of its 5-year range (-50.49%–-13.85%).
66.55% below its 12-month average of -30.32%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -11.62%.
RETURN ON ASSETS (ROA)
-50.49%
RETURN ON ASSETS (ROA) AVG TTM
-30.32%
RETURN ON ASSETS (ROA) AVG 3Y
-31.10%
RETURN ON ASSETS (ROA) AVG 5Y
-27.11%
RETURN ON ASSETS (ROA) AVG 10Y
-29.48%
RETURN ON ASSETS (ROA) AVG 15Y
-33.37%
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-66.55%
CURRENT VS 3Y AVG
-62.35%
CURRENT VS 5Y AVG
-86.22%
CURRENT VS 10Y AVG
-71.27%
CURRENT VS 15Y AVG
-51.30%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-28.05%
median of 558 covered companies
CURRENT VS SECTOR MEDIAN
-80.03%
vs the sector median at left
Kura Oncology, Inc.
Market Cap
$935.68M
Return on Assets (ROA)
-50.49%
TTM Avg
-30.32%
3Y Avg
-31.10%
5Y Avg
-27.11%
Market Cap
$938.73M
Return on Assets (ROA)
-45.94%
TTM Avg
-39.23%
3Y Avg
-37.58%
5Y Avg
-117.41%
Market Cap
$937.09M
Return on Assets (ROA)
-39.67%
TTM Avg
-22.62%
3Y Avg
-34.56%
5Y Avg
-34.56%
Market Cap
$913.56M
Return on Assets (ROA)
4.06%
TTM Avg
3.72%
3Y Avg
3.23%
5Y Avg
2.82%
Market Cap
$901.56M
Return on Assets (ROA)
8.09%
TTM Avg
-0.64%
3Y Avg
-8.03%
5Y Avg
-4.54%
Market Cap
$975.17M
Return on Assets (ROA)
-13.12%
TTM Avg
-18.77%
3Y Avg
-18.48%
5Y Avg
-18.48%
Market Cap
$999.08M
Return on Assets (ROA)
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$888.92M
Return on Assets (ROA)
55.85%
TTM Avg
-44.25%
3Y Avg
-43.62%
5Y Avg
-43.05%
Market Cap
$875.38M
Return on Assets (ROA)
-22.62%
TTM Avg
-55.95%
3Y Avg
-57.94%
5Y Avg
-46.38%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Kura Oncology, Inc. (KURA) | $935.68M | -50.49% | -30.32% | -31.10% | -27.11% |
| MoonLake Immunotherapeutics (MLTX)vs › | $938.73M | -45.94% | -39.23% | -37.58% | -117.41% |
| CeriBell, Inc. (CBLL)vs › | $937.09M | -39.67% | -22.62% | -34.56% | -34.56% |
| HealthStream, Inc. (HSTM)vs › | $913.56M | 4.06% | 3.72% | 3.23% | 2.82% |
| Bioventus Inc. (BVS)vs › | $901.56M | 8.09% | -0.64% | -8.03% | -4.54% |
| Aktis Oncology, Inc. (AKTS)vs › | $975.17M | -13.12% | -18.77% | -18.48% | -18.48% |
| Latigo Biotherapeutics Inc. (LTGO)vs › | $999.08M | N/A | N/A | N/A | N/A |
| Arbutus Biopharma Corp (ABUS)vs › | $888.92M | 55.85% | -44.25% | -43.62% | -43.05% |
| Corvus Pharmaceuticals, Inc. (CRVS)vs › | $875.38M | -22.62% | -55.95% | -57.94% | -46.38% |
| LB Pharmaceuticals Inc Common Stock (LBRX)vs › | $986.19M | -23.69% | -98.11% | -69.18% | -69.18% |
ROA
-50.5%
ROE
-612.8%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -37.74% |
| 2024-12-31 | -22.89% |
| 2023-12-31 | -34.00% |
| 2022-12-31 | -29.77% |
| 2021-12-31 | -24.43% |
| 2020-12-31 | -13.85% |
| 2019-12-31 | -26.09% |
| 2018-12-31 | -33.14% |
| 2017-12-31 | -36.97% |
| 2016-12-31 | -39.47% |
| 2015-12-31 | -25.93% |
| 2014-12-31 | -799.20% |
| 2013-12-31 | -301.22% |
| 2012-12-31 | -325.70% |
| 2011-12-31 | -333.26% |
| 2010-12-31 | -76.18% |
| 2009-12-31 | -153.61% |
| 2008-12-31 | -447.83% |
